Skip to main content

Key Product Details

Species Reactivity

Human

Applications

CyTOF-ready, Flow Cytometry

Label

Allophycocyanin (Excitation = 620-650 nm, Emission = 660-670 nm)

Antibody Source

Recombinant Monoclonal Mouse IgG1 Clone # 541522

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived recombinant human VSIG2
Val24-Ala243
Accession # Q961Q7-1

Specificity

Detects human VSIG2 in direct ELISAs.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Applications for VSIG2 Antibody (541522) [Allophycocyanin]

Application
Recommended Usage

CyTOF-ready

Optimal dilutions of this antibody should be experimentally determined.

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Formulation

PBS

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: VSIG2

Long Name

V-Set and Immunoglobulin Domain Containing 2

Alternate Names

CTH, CTXL

Additional VSIG2 Products

Product Documents for VSIG2 Antibody (541522) [Allophycocyanin]

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for VSIG2 Antibody (541522) [Allophycocyanin]

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...